We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Rite Aid (RAD) Return to Solid Trend with Q2 Earnings?
Read MoreHide Full Article
Drug store retailer, Rite Aid Corporation is slated to report second-quarter fiscal 2017 results on Sep 22. In the last quarter, the company delivered a negative earnings surprise of 16.7%, which marked its first earnings miss after seven consecutive beats. Let’s see how things are shaping up for this announcement.
Rite Aid’s earnings in the last quarter were a letdown mainly owing to pharmacy reimbursement rate pressures, as drug purchasing efficiencies were short of expectations. Further, management anticipates drug cost reductions to remain below expectations in the near term, though an improvement is likely in second-half fiscal 2017. Nonetheless, these factors raise concerns about the company’s upcoming performance. Also, risks related to greater industry consolidation and competition remain threats for Rite Aid.
However, the company’s constant focus on strengthening its portfolio of health and wellness services, coupled with its consistent endeavors to enhance pharmacy and clinical services bode well. So, let’s see if Rite Aid’s upcoming release can get it back to its positive surprise trajectory.
Earnings Whispers
Our proven model does not conclusively show that Rite Aid is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. This is not the case here, as you will see below:
Zacks ESP: Rite Aid currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 3 cents.
Zacks Rank: Rite Aid carries a Zacks Rank #3 (Hold), which increases the predictive power of ESP. However, the company’s ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks that Warrant a Look
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:
Coca-Cola European Partners Plc has an Earnings ESP of +4.11% and a Zacks Rank #3.
Finish Line Inc. has an Earnings ESP of +1.89% and a Zacks Rank #3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand.Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Can Rite Aid (RAD) Return to Solid Trend with Q2 Earnings?
Drug store retailer, Rite Aid Corporation is slated to report second-quarter fiscal 2017 results on Sep 22. In the last quarter, the company delivered a negative earnings surprise of 16.7%, which marked its first earnings miss after seven consecutive beats. Let’s see how things are shaping up for this announcement.
RITE AID CORP Price and EPS Surprise
RITE AID CORP Price and EPS Surprise | RITE AID CORP Quote
Factors Influencing This Quarter
Rite Aid’s earnings in the last quarter were a letdown mainly owing to pharmacy reimbursement rate pressures, as drug purchasing efficiencies were short of expectations. Further, management anticipates drug cost reductions to remain below expectations in the near term, though an improvement is likely in second-half fiscal 2017. Nonetheless, these factors raise concerns about the company’s upcoming performance. Also, risks related to greater industry consolidation and competition remain threats for Rite Aid.
However, the company’s constant focus on strengthening its portfolio of health and wellness services, coupled with its consistent endeavors to enhance pharmacy and clinical services bode well. So, let’s see if Rite Aid’s upcoming release can get it back to its positive surprise trajectory.
Earnings Whispers
Our proven model does not conclusively show that Rite Aid is likely to beat earnings this quarter. This is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1, 2 or 3 for this to happen. This is not the case here, as you will see below:
Zacks ESP: Rite Aid currently has an Earnings ESP of 0.00%. This is because both the Most Accurate estimate and the Zacks Consensus Estimate stand at 3 cents.
Zacks Rank: Rite Aid carries a Zacks Rank #3 (Hold), which increases the predictive power of ESP. However, the company’s ESP of 0.00% makes surprise prediction difficult.
We caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks that Warrant a Look
Here are some companies you may want to consider as our model shows that these have the right combination of elements to post an earnings beat:
Coca-Cola European Partners Plc has an Earnings ESP of +4.11% and a Zacks Rank #3.
Carnival Corp. (CCL - Free Report) has an Earnings ESP of +2.13% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Finish Line Inc. has an Earnings ESP of +1.89% and a Zacks Rank #3.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>